

ADENOSINE,
CARDIOPROTECTION AND ITS
CLINICAL APPLICATION

Developments in Cardiovascular Medicine

- M.LeWinter, H. Suga and M.W. Watkins (eds.): *Cardiac Energetics: From Emax to Pressure-volume Area*. 1995 ISBN 0-7923-3721-2
- R.J. Siegel (ed.): *Ultrasound Angioplasty*. 1995 ISBN 0-7923-3722-0
- D.M. Yellon and G.J. Gross (eds.): *Myocardial Protection and the Katp Channel*. 1995 ISBN 0-7923-3791-3
- A.V.G. Brusckhe, J.H.C. Reiber, K.I. Lie and H.J.J. Wellens (eds.): *Lipid Lowering Therapy and Progression of Coronary Atherosclerosis*. 1996 ISBN 0-7923-3807-3
- A.S.A. Abd-Elfattah and A.S. Wechsler (eds.): *Purines and Myocardial Protection*. 1995 ISBN 0-7923-3831-6
- M. Morad, S. Ebashi, W. Trautwein and Y. Kurachi (eds.): *Molecular Physiology and Pharmacology of Cardiac Ion Channels and Transporters*. 1996 ISBN 0-7923-3913-4
- A.M. Oto (ed.): *Practice and Progress in Cardiac Pacing and Electrophysiology*. 1996 ISBN 0-7923-3950-9
- W.H. Birkenhager (ed.): *Practical Management of Hypertension. Second Edition*. 1996 ISBN 0-7923-3952-5
- J.C. Chatham, J.R. Forder and J.H. McNeill(eds.):*The Heart In Diabetes*. 1996 ISBN 0-7923-4052-3
- M. Kroll, M. Lehmann (eds.): *Implantable Cardioverter Defibrillator Therapy: The Engineering-Clinical Interface*. 1996 ISBN 0-7923-4300-X
- Lloyd Klein (ed.): *Coronary Stenosis Morphology: Analysis and Implication*. 1996 ISBN 0-7923-9867-X
- Johan H.C. Reiber, Ernst E. Van der Wall (eds.): *Cardiovascular Imaging*. 1996 ISBN 0-7923-4109-0
- A.-M. Salmasi, A. Strano (eds.): *Angiology in Practice*. ISBN 0-7923-4143-0
- Julio E. Perez, Roberto M. Lang, (eds.): *Echocardiography and Cardiovascular Function: Tools for the Next Decade*. 1996 ISBN 0-7923-9884-X
- Keith L. March (ed.): *Gene Transfer in the Cardiovascular System: Experimental Approaches and Therapeutic Implications*. 1997 ISBN 0-7923-9859-9
- Anne A. Knowlton (ed.): *Heat Shock Proteins and the Cardiovascular System*. 1997 ISBN 0-7923-9910-2
- Richard C. Becker (ed.): *The Textbook of Coronary Thrombosis and Thrombolysis*. 1997 ISBN 0-7923-9923-4
- Robert M. Mentzer, Jr., Masafumi Kitakaze, James M. Downey, Masatsugu Hori, (eds): *Adenosine, Cardioprotection and its Clinical Application* ISBN 0-7923-9954-4

ADENOSINE, CARDIOPROTECTION AND ITS CLINICAL APPLICATION

Edited by

Robert M. Mentzer, Jr.
University of Kentucky

Masafumi Kitakaze
Osaka University School of Medicine

James M. Downey
University of South Alabama

Masatsugu Hori
Osaka University School of Medicine

Library of Congress Cataloging-in-Publication Data

A C.I.P. Catalogue record for this book is available
from the Library of Congress.

ISBN 978-1-4613-4676-0 ISBN 978-1-4419-8736-5 (eBook)

DOI 10.1007/978-1-4419-8736-5

Copyright © 1997 by Springer Science+Business Media New York

Originally published by Kluwer Academic Publishers in 1997

Softcover reprint of the hardcover 1st edition 1997

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher, SPRINGER SCIENCE+BUSINESS MEDIA, LLC

Printed on acid-free paper.

CONTENTS

Contributing Authors	ix
Preface	xiii
Acknowledgements	xv

I.	ADENOSINE AND CARDIOPROTECTION	
1.	Adenosine and Cardioprotection	3
	<i>Robert M. Mentzer, Jr. and Robert Lasley</i>	
II.	CARDIOPROTECTION AND MECHANISMS OF ISCHEMIC AND REPERFUSION INJURY	
2.	Concept of Cardioprotection Against Myocardial Ischemia	19
	<i>Masatsugu Hori</i>	
3.	The Late Phase of Preconditioning Against Myocardial Stunning	29
	<i>Roberto Bolli, Xian-Liang Tang, Yumin Qiu , and Seong-Wook Park</i>	
4.	Coronary Perfusion as the Major Determinant of Myocardial Contractility in the Heart: Implication for Myocardial Hibernation	37
	<i>Masafumi Kitakaze</i>	
5.	Myocardial Protection From Reperfusion Injury With Adenosine	49
	<i>Jakob Vinten-Johansen and Zhi-Qing Zhao</i>	
III.	CELLULAR MECHANISMS OF CARDIOPROTECTION IN ISCHEMIC PRECONDITIONING	
6.	Protein Kinase C - the Key-Enzyme in Ischemic Preconditioning?	73
	<i>Christof Weinbrenner and James M. Downey</i>	

CONTENTS

7. Adenosine, Cardioprotection and Potential Mechanisms <i>Robert Lasley</i>	93
8. Activation of Ecto-5'-nucleotidase Mediates Cardioprotection in Ischemic Preconditioning: Important Role of Protein Kinase C <i>Masafumi Kitakaze, Tetsuo Minamino, Koichi Node, Hiroharu Funaya, and Masatsugu Hori</i>	103
9. Role of Mn-SOD Induction in the Second Window Phenomenon of Preconditioning of Ischemic Hearts <i>Tsunehiko Kuzuya, Masashi Nishida, Shiro Hoshida, Nobushige Yamashita, and Michihiko Tada</i>	115
10. Opioid Receptors, K_{ATP} Channels and Ischemic Preconditioning <i>Garrett J. Gross and Jo El Schultz</i>	125
11. Bradykinin and Preconditioning Against Infarction <i>Tetsuji Miura, Jun Sakamoto, and Takayuki Miki</i>	133
12. Preconditioning in Human Muscle and Myocytes <i>Cornelia S Carr and Derek M Yellon</i>	141
13. Protein Kinase C and Adenosine Synergistically Activate ATP-Sensitive Potassium Currents: Implications for Ischemic Preconditioning <i>Yongge Liu, Wei Dong Gao, Brian O'Rourke, and Eduardo Marban</i>	153
IV. CLINICAL APPLICATION OF NEW STRATEGIES TO PROTECT THE ISCHEMIC HEART	
14. Adenosine and Myocardial Protection in Humans <i>Robert M. Mentzer, Jr. and Robert D. Lasley</i>	167
15. Clinical Applications of Ischemic Preconditioning <i>Yochai Birnbaum and Robert A. Kloner</i>	177
16. Clinical Pharmacology of Preconditioning and Adenosinergic Drugs <i>Herman Van Belle</i>	187

CONTENTS

17. Clinical Application of Ischemic Preconditioning by ATP-Sensitive Potassium Channel Openers <i>Naoshi Arakawa, Motoyuki Nakamura, Ken-ichi Fukami, and Katsuhiko Hiramori</i>	197
18. Potassium Channel Openers and Cardiac Surgery <i>Louis P. Perrault and Philippe Menasché</i>	203
19. Anti-ischemic Effects of the ATP-sensitive Potassium Channel Opener During Coronary Angioplasty <i>Satoshi Saito, Tsuneo Mizumura, Tadateru Takayama, Junko Honye, Masahito Moriuchi, Yukio Ozawa, and Katsuo Kanmatsuse</i>	219
20. Clinical Impact of Ischemic Preconditioning on Infarct Size and Coronary No-reflow Phenomenon after Successful Recanalization in the Acute Myocardial Infarction <i>Kazuo Komamura, Kazuhisa Kodama, Masafumi Kitakaze, and Masatsugu Hori</i>	225
Index	237

CONTRIBUTING AUTHORS

ARAKAWA, Naoshi, Second Department of Internal Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate 020, Japan

BIRNBAUM, Yochai, The Heart Institute, Good Samaritan Hospital, 1225 Wilshire Blvd., Los Angeles, CA 90017, U.S.A.

BOLLI, Roberto, University of Louisville School of Medicine, ACB Third Floor, 550 South Jackson Street, Louisville, KY 40292, U.S.A.

CARR, Cornelia, The Hatter Institute, University College London, Grafton Way, London, WC1E 6DB, United Kingdom

DOWNEY, James, Department of Physiology, MSB 3024, University of South Alabama, College of Medicine, Mobile, AL 36688, U.S.A.

FUKAMI, Ken-ichi, Second Department of Internal Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate/020, Japan

FUNAYA, Hiroharu, The First Department of Medicine, Osaka University School of Medicine, 2-2 Yamadaoka, Suita 565, Japan

GAO, Wei Dong, Department of Medicine, Johns Hopkins University, 720 Rutland Ave., Ross 844, Baltimore, MD 21205, U.S.A.

GROSS, Garrett, Department of Pharmacology and Toxicology, Medical College of Wisconsin, P.O. Box 26509, Milwaukee, WI 53226-0509, U.S.A.

HIRAMORI, Katsuhiko, Second Department of Internal Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate 020, Japan

HONYE, Junko, The 2nd Department of Medicine, Nihon University School of Medicine, Oyaguchi-Kami 30-1, Itabashi-ku, Tokyo 173, Japan

HORI, Masatsugu, The First Department of Medicine, Osaka University School of Medicine, 2-2 Yamadaoka, Suita 565, Japan

CONTRIBUTING AUTHORS

HOSHIDA, Shiro, Department of Medicine and Pathophysiology, Osaka University School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565, Japan

KANMATSUSE, Katsuo, The 2nd Department of Medicine, Nihon University School of Medicine, Oyaguchi-Kami 30-1, Itabashi-ku, Tokyo 173, Japan

KITAKAZE, Masafumi, The First Department of Medicine, Osaka University School of Medicine, 2-2 Yamadaoka, Suita 565, Japan

KLONER, Robert A., The Heart Institute, Good Samaritan Hospital, 1225 Wilshire Blvd., Los Angeles, CA 90017, U.S.A.

KODAMA, Kazuhisa, Division of Cardiology, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565, Japan

KOMAMURA, Kazuo, Division of Cardiology, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565, Japan

KUZUYA, Tsunehiko, Department of Medicine and Pathophysiology, Osaka University School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565, Japan

LASLEY, Robert D., University of Kentucky Medical Center, 800 Rose Street, Room MN-260, Lexington, KY 40536-0084, U.S.A.

LIU, Yongge, Department of Medicine, Johns Hopkins University, 720 Rutland Ave., Ross 844, Baltimore, MD 21205, U.S.A.

MARBAN, Eduardo, Department of Medicine, Johns Hopkins University, 720 Rutland Ave., Ross 844, Baltimore, MD 21205, U.S.A.

MENASCHE, Philippe, Department of Cardiovascular Surgery, Hôpital Lariboisière, 2 rue Ambroise Paré, 75010, Paris, France

MENTZER, Jr., Robert M., University of Kentucky Medical Center, 800 Rose Street, Room MN-264, Lexington, KY 40536-0084, U.S.A.

MIKI, Takayuki, Second Department of Internal Medicine, Sapporo Medical University School of Medicine, South-1 West-16, Chuo-ku, Sapporo 060, Japan

MINAMINO, Tetsuo, The First Department of Medicine, Osaka University School of Medicine, 2-2 Yamadaoka, Suita 565, Japan

CONTRIBUTING AUTHORS

MIURA, Tetsuji, Second Department of Internal Medicine, Sapporo Medical University School of Medicine, South-1 West-16, Chuo-ku, Sapporo 060, Japan

MIZUMURA, Tsuneo, The 2nd Department of Medicine, Nihon University School of Medicine, Oyaguchi-Kami 30-1, Itabashi-ku, Tokyo 173, Japan

MORIUCHI, Masahito, The 2nd Department of Medicine, Nihon University School of Medicine, Oyaguchi-Kami 30-1, Itabashi-ku, Tokyo 173, Japan

NAKAMURA, Motoyuki, Second Department of Internal Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate 020, Japan

NISHIDA, Masashi, Department of Medicine and Pathophysiology, Osaka University School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565, Japan

NODE, Koichi, The First Department of Medicine, Osaka University School of Medicine, 2-2 Yamadaoka, Suita 565, Japan

O'ROURKE, Brian, Department of Medicine, Johns Hopkins University, 720 Rutland Ave., Ross 844, Baltimore, MD 21205, U.S.A.

OZAWA, Yukio, The 2nd Department of Medicine, Nihon University School of Medicine, Oyaguchi-Kami 30-1, Itabashi-ku, Tokyo 173, Japan

PARK, Seong-Wook, University of Louisville School of Medicine, ACB Third Floor, 550 South Jackson Street, Louisville, KY 40292, U.S.A.

PERRAULT, Louis P., Department of Cardiovascular Surgery, Hôpital Lariboisière, 2 rue Ambroise Paré, 75010, Paris, France

QIU, Yumin, University of Louisville School of Medicine, ACB Third Floor, 550 South Jackson Street, Louisville, KY 40292, U.S.A.

SAITO, Satoshi, The 2nd Department of Medicine, Nihon University School of Medicine, Oyaguchi-Kami 30-1, Itabashi-ku, Tokyo 173, Japan

SAKAMOTA, Jun, Second Department of Internal Medicine, Sapporo Medical University School of Medicine, South-1 West-16, Chuo-ku, Sapporo 060, Japan

SCHULTZ, Jo El, Department of Pharmacology and Toxicology, Medical College of Wisconsin, P.O. Box 26509, Milwaukee, WI 53226-0509, U.S.A.

CONTRIBUTING AUTHORS

TADA, Michihiko, Department of Medicine and Pathophysiology, Osaka University School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565, Japan

TAKAYAMA, Tadateru, The 2nd Department of Medicine, Nihon University School of Medicine, Oyaguchi-Kami 30-1, Itabashi-ku, Tokyo 173, Japan

TANG, Xian-Liang, University of Louisville School of Medicine, ACB Third Floor, 550 South Jackson Street, Louisville, KY 40292, U.S.A.

VAN BELLE, Herman, Janssen Research Foundation, Turnhoutseweg 30, B-2340, Beerse, Belgium

VINTEN-JOHANSEN, Jakob, Section of Cardiothoracic Surgery, Carlyle Fraser Heart Center of Emory University, Cardiothoracic Research Laboratory, Atlanta, GA 30365-2225, U.S.A.

WEINBRENNER, Christof, Department of Physiology, MSB 3024, University of South Alabama, College of Medicine, Mobile, AL 36688, U.S.A.

YAMASHITA, Nobushige, Department of Medicine and Pathophysiology, Osaka University School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565, Japan

YELLON, Derek, The Hatter Institute, University College London, Grafton Way, London, WC1E 6DB, United Kingdom

ZHAO, Zhi-Qing, Section of Cardiothoracic Surgery, Carlyle Fraser Heart Center of Emory University, Cardiothoracic Research Laboratory, Atlanta, GA 30365-2225, U.S.A.

PREFACE

It has been almost 15 years since the first reports appeared indicating that adenosine exerted a protective effect in ischemic and reperfused myocardium. Numerous experimental studies have shown that adenosine (both exogenous and endogenous adenosine) delays the onset of ischemic contracture, modulates myocardial metabolism during ischemia, attenuates reversible postischemic ventricular dysfunction (myocardial stunning), and reduces myocardial infarct size. Initial studies on adenosine's cardioprotective effect were based on its ability to stimulate postischemic ATP resynthesis, increase coronary blood flow, and reduce heart rate. Although these actions of adenosine are undoubtedly beneficial to the ischemic/reperfused heart, it now appears that adenosine's cardioprotective effect may be exclusive of these properties.

The immense growth in the number of articles on adenosine cardioprotection in the last several years has been related in large part to the hypothesis that adenosine plays a role in ischemic preconditioning. Ischemic preconditioning is the phenomenon in which a brief period of ischemia (and reperfusion) prior to a more prolonged occlusion reduces myocardial infarct size. This form of myocardial protection has received much interest because ischemic preconditioning has been shown to be the most potent means of reducing infarct size in all animal models thus far tested. In fact prior to studies implicating adenosine's role in ischemic preconditioning, adenosine's infarct reducing effect was not well recognized.

Since 1990, the principal focus of adenosine cardioprotection research has centered on the role of adenosine receptors. It is currently thought that adenosine protects the ischemic heart primarily via the activation of adenosine A₁ receptors located on the cardiac myocytes. There are some reports however that adenosine A₂ receptor activation during reperfusion may reduce the extent of myocardial infarction. Still other reports suggest that adenosine may exert its protective effects via stimulation of an adenosine A₃ receptor subtype. Although the majority of evidence suggests involvement of the A₁ receptor, the intracellular signal transduction pathway(s) responsible for adenosine's beneficial effect in ischemic/reperfused myocardium remains unknown. There is evidence for the involvement of ATP-sensitive potassium (K_{ATP}) channels, however there appear to be species differences. There is also evidence for the modulation of calcium

PREFACE

dependent protein kinase (PKC), however there are also controversies regarding this potential mechanism. There are also some differences between ischemic preconditioning, and treatments with K_{ATP} channel openers and adenosine.

Adenosine is used clinically for terminating supraventricular tachycardia, as a diagnostic tool in coronary imaging, and has been used postoperatively for blood pressure control after heart surgery. There are also recent reports that adenosine may be safely tolerated and a potentially beneficial additive to cardioplegic solutions during open heart surgery in humans. There is even evidence that ischemic preconditioning may occur in humans under various clinical situations.

This book contains chapters from contributors to the first three symposia on "Adenosine, Cardioprotection, and its Clinical Application". All aspects of adenosine cardioprotection and ischemic preconditioning, including potential mechanisms and clinical applications, are discussed by experts in these areas. The reader will find this book to be both an excellent source of information on these topics, as well a guide to future experiments.

The editors would like to thank the contributors for their chapters and the symposia attendees for their interest in these topics. We would also like to thank the sponsors and supporters who made these symposia possible. The editors would also like to express their gratitude to Steve Thomas for his assistance in preparing this book.

Robert M. Mentzer, Jr.
Masafumi Kitakaze
James M. Downey
Masatsugu Hori

ACKNOWLEDGEMENTS

The editors of this book would like to thank Chugai Pharmaceuticals for their generous underwriting support for this book. Without their assistance, this book and the Symposia would not have been possible.

The First, Second, and Third International Symposia on Adenosine, Cardioprotection and Its Clinical Application were supported by the following:

Chugai Pharmaceuticals

KOWA Company

Medco Research, Inc.

Fujisawa USA, Inc.

Bayer Corporation

Sanofi Pharmaceuticals

Cardiothoracic and Vascular Surgery Council and the Circulation Council of the American Heart Association

The editors gratefully acknowledge the assistance of Stephen K. Thomas in editing, formatting, and assembling the finished book.

Special thanks also to Mr. Thomas, Penelope Cook, and Joann Slack for their tireless efforts in coordinating the Symposia.